breast-cancer
(15)
Amwise Diagnostic PTE. LTD.
Amwise Diagnostic is a Singapore- and Taipei-based cancer genomics company behind RecurIndex, a multi-gene test built specifically on the genomes of Asian breast cancer patients. It reads a tumor's genetic profile alongside clinical factors to estimate the five-year risk of local recurrence and distant metastasis, helping physicians and patients decide whether chemotherapy or radiotherapy is actually needed - and helping many avoid treatment they don't.
Ataraxis AI
Ataraxis AI is a New York-based precision-oncology company building AI-native cancer diagnostics. Founded in 2022 by physician-scientist Jan Witowski and AI researcher Krzysztof Geras, it developed Kestrel, a digital-pathology foundation model trained on hundreds of millions of tissue images. Its flagship platform, Ataraxis Breast, reads standard pathology slides to predict recurrence risk and estimate whether an individual patient will benefit from chemotherapy - reported to be roughly 30% more accurate than the current standard of care - returning results within about an hour and without additional tissue procedures.
Shorla Oncology
Shorla Oncology is a specialty pharmaceutical company based in Clonmel, Ireland, with a U.S. base in Cambridge, Massachusetts, that develops and commercializes innovative oncology drugs for orphan and pediatric cancers. Founded in 2018 by Sharon Cunningham and Orlaith Ryan, Shorla focuses on indications where existing treatments are limited, in shortage, or poorly suited to patients - reformulating and reinventing cancer therapies into easier-to-administer forms such as oral liquids and ready-to-dilute vials. The company markets four FDA-approved products in the U.S. and is advancing an early-stage pipeline addressing rare cancers.
SpotitEarly
SpotitEarly is a healthtech company building an accessible, non-invasive early cancer detection service that combines trained scent-detection beagles with an AI platform to analyze volatile organic compounds (VOCs) in a person's breath. Users collect a breath sample at home and mail it to the company's lab, where beagles screen for cancer-linked odors and SpotitEarly's proprietary LUCID bio-AI platform digitizes and interprets the dogs' behavioral signals. A double-blind clinical study of 1,400 people, published in Nature's Scientific Reports, reported 94% sensitivity and specificity across the four most common cancers - breast, colorectal, lung, and prostate. Founded in Israel and now launching in the U.S., the company aims to make routine multi-cancer pre-screening affordable, at roughly $250 for a single test.
Katherine Bowdish
Katherine (Kathy) Bowdish is a molecular geneticist and biopharmaceutical leader who serves as President and CEO of PIC Therapeutics, a Natick, Massachusetts biotech developing cancer drugs that work by modulating RNA translation - targeting the eIF4E 'master switch' that tumors use to overproduce oncogene proteins. Over more than two decades she has founded and led a string of early-stage life science companies including Prolifaron (acquired by Alexion), Anaphore and Permeon Biologics, and she built and ran Sanofi Sunrise, the pharma giant's early-stage venture and partnering arm. She holds a PhD in molecular genetics from Columbia and led PIC through a $35 million Series A to push its lead program toward the clinic in drug-resistant breast cancer.
ARNA Genomics US Inc.
ARNA Genomics US Inc. is a San Francisco-based biotechnology company developing multiomics liquid-biopsy technology for early cancer detection. Its lead assay, ARNA Breast, analyzes cell-free DNA and plasma enzyme activity from a routine blood draw to flag early-stage breast cancer, with proof-of-concept studies reporting sensitivity above 90%. Founded in 2013 and led by CEO Egor Melnikov, the company raised a $3.5M Series A in 2020 to fund clinical validation.
Manta Cares
Manta Cares is a San Francisco-based digital health company redesigning the cancer experience for patients and caregivers. Founded by breast cancer survivor Samira Daswani, it offers a free, HIPAA-compliant, AI-enabled platform - featuring subway-style Cancer Maps, a symptom and appointment planner, and expert-reviewed resources vetted by 100+ oncologists - that turns the chaotic cancer journey into a navigable path. The company launched publicly in November 2025 with an oversubscribed $5.4M seed round led by Pear VC and Sozo Ventures.
Adam Yala
Adam Yala is a UC Berkeley and UCSF assistant professor of Computational Precision Health turned founder, now CEO of Voio, a Berkeley AI startup building frontier radiology models. At MIT he created Mirai and Sybil, open-source AI tools that flag breast and lung cancer risk years early and are now studied at more than 90 hospitals across 30 countries. In late 2025 Voio emerged from stealth with $8.6M in seed funding and Pillar-0, billed as the most accurate open AI model for radiology, with a mission to make being a radiologist more empowering rather than to replace the profession.
Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company based in San Francisco that develops targeted small-molecule therapies for ER+/HER2- metastatic breast cancer and other women's cancers. Its lead candidate, palazestrant (OP-1250), is an oral complete estrogen receptor antagonist and selective ER degrader now in two Phase 3 trials, while a second program, OP-3136, is a KAT6 inhibitor in Phase 1. Olema's bet is that better-designed oral endocrine therapy can overcome the resistance that limits today's standard of care.
858 Therapeutics
858 Therapeutics is a clinical-stage biotechnology company in San Diego building small-molecule cancer drugs aimed at novel targets in DNA damage response, RNA modulation, and innate immunity. Its lead candidate, the oral PARG inhibitor ETX-19477, is in a first-in-human Phase 1/2 trial for advanced solid tumors and has won FDA Fast Track designation for BRCA-mutated, platinum-resistant ovarian cancer. Founded in 2019 by a serial team of San Diego drug developers, the company has raised $110 million across Series A and B financings.
Edgewood Oncology
Edgewood Oncology is a clinical-stage biotechnology company developing BTX-A51, a first-in-class oral small-molecule multi-kinase inhibitor that co-targets casein kinase 1 alpha (CK1α) and cyclin-dependent kinases 7 and 9 (CDK7/CDK9) - three master regulators of cancer cell survival and transcription. Founded by veteran biotech executive David N. Cook and emerging from stealth in March 2024 with $20M in Series A financing from Alta Partners, the company is advancing BTX-A51 through Phase 2a trials in relapsed/refractory acute myeloid leukemia and genetically-defined (GATA3-mutant) ER+/HER2- metastatic breast cancer.
Totus Medicines
Totus Medicines is a clinical-stage precision medicines company in Emeryville, California, building covalent small-molecule drugs against historically undruggable targets. Its AI-powered OmniDEL platform screens billions of DNA-encoded covalent candidates against thousands of targets inside living cells, surfacing molecules that older methods miss. Its lead program, TOS-358, is the first and only covalent PI3Ka inhibitor in clinical development, showing class-leading tolerability and strong disease control in breast, endometrial, and head & neck cancers.
Connie Lehman
Connie Lehman is a radiologist who spent three decades reading mammograms and decided the picture could tell a different story. As founder and CEO of Boston-based Clairity, she built the first FDA-authorized AI platform that reads a routine screening mammogram and estimates a woman's five-year risk of developing breast cancer, spotting tissue patterns invisible to the human eye. A Professor of Radiology at Harvard Medical School with more than 300 peer-reviewed publications, she left a celebrated academic career to commercialize the idea that imaging should predict cancer, not just find it. TIME named her to its 2026 TIME100 Health list and Forbes to its 50 Over 50: Innovation list.
Julián Ríos Cantú
Julián Ríos Cantú is the co-founder and CEO of Eden, the leading cloud-native radiology operating system in Latin America. Motivated by his mother's battle with breast cancer, he began building health technology at age 16, went on to become the youngest-ever winner of the Global Student Entrepreneur Awards at 18, earned a Thiel Fellowship, and went through Y Combinator in 2018. Today, Eden processes over 13 million diagnostic studies annually across 18 countries for more than 2,200 medical institutions, backed by Sierra Ventures, Khosla Ventures, Kaszek, and notable angel investors including Leonardo DiCaprio, Ashton Kutcher, and Tony Robbins.
Sean P. Bohen
Sean P. Bohen is President and CEO of Olema Oncology, a San Francisco clinical-stage biopharmaceutical company developing targeted therapies for women's cancers. An MD/PhD oncologist who spent 13 years at Genentech and four as AstraZeneca's Chief Medical Officer, he is now steering Olema's lead drug palazestrant - an oral complete estrogen receptor antagonist - through Phase 3 trials in ER+/HER2- metastatic breast cancer.